A study to assess the safety and pharmacokinetics of verinurad and allopurinol in Asian and Chinese subjects

Trial Identifier: D5495C00006
Sponsor: AstraZeneca
Collaborator:
PAREXEL Early Phase Clinical Unit
NCTID:: NCT03836599
Start Date: January 2019
Primary Completion Date: April 2019
Study Completion Date: April 2019
Condition: Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Japanese Translation
Korean Translation
Chinese Translation
Traditional Chinese Translation

Trial Locations

Country Location
United States of America, CA Glendale, CA, United States of America, 91206